Sunpeaks Ventures Announces Clotamin to be Sold in Approximately 70 Discount Drug Mart Locations in Ohio - Professional Sports Team Marketing Campaign Expected to Increase Sales

SILVER SPRING, Md., March 12, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that Clotamin® will soon be available in approximately 70 Discount Drug Mart ("DDM") retail locations in Ohio.  In addition, Clotamin will be included in the Pro Points Program, DDM's signature customer rewards program.  DDM customers may redeem their Pro Points for merchandise, game tickets, and one-of-a-kind lifetime experiences with professional local sports teams including the Indians, Cavaliers, Browns, Lake Erie Monsters (hockey), and Cleveland Gladiators (arena football).  Pro Points rewards include the opportunity to shoot hoops on the Cleveland Cavaliers basketball court before warm-ups and autographed baseballs from your favorite Cleveland Indians baseball players.  Participating partner companies are included in a comprehensive advertising campaign at all participating team events.  The complete advertising campaign is valued up to $250,000 and could have an incremental sales increase of up to 60%, according to DDM.

"DDM is one of the leading retailers in the Ohio market and their Pro Points Program really separates them from their local competition," stated Mackie A. Barch, CEO of Sunpeaks.  "The Pro Points Program will allow Clotamin to be marketed simultaneously to multiple professional sports team fan bases and represents an entirely new potential customer audience for Clotamin.  This could have major positive sales implications for Clotamin and provides excellent advertising value for the Company and it shareholders."

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners).  According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or [email protected]

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.